SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSIS
单位：[1]Phase I Clinical Research Center, The First Hospital of Jilin University,[2]Guangdong Raynovent Biotech Co.,Ltd.[3]Nafang Hospital,Nanfang Medical University,[4]Beijing Friendship Hospital,Capital Medical University,首都医科大学附属北京友谊医院[5]Department of Radiology, The First Hospital of Jilin University,[6]Department of Hepatology, The First Hospital of Jilin University
第一作者单位：[1]Phase I Clinical Research Center, The First Hospital of Jilin University,
推荐引用方式(GB/T 7714)：
Yue Hu,Haijun Li,Hong Zhang,et al.SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSIS[J].HEPATOLOGY.2021,74:1150A-1150A.
APA：
Yue Hu,Haijun Li,Hong Zhang,Jinjun Chen,Zhongyuan Xu...&Yanhua Ding.(2021).SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSIS.HEPATOLOGY,74,
MLA：
Yue Hu,et al."SAFETY, PHARMACOKINETICS AND EFFICACY OF THE NOVEL PAN-PHOSPHODIESTERASE INHIBITOR ZSP1601 IN 36 NASH PATIENTS: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, MULTIPLE-DOSE ESCALATION PHASE IB STUDY INTERIM ANALYSIS".HEPATOLOGY 74.(2021):1150A-1150A
医学